ロード中…
Oncolytic Adenoviruses for Cancer Therapy
Many immuno-therapeutic strategies are currently being developed to fight cancer. In this scenario, oncolytic adenoviruses (Onc.Ads) have an interesting role for their peculiar tumor selectivity, safety, and transgene-delivery capability. The major strength of the Onc.Ads is the extraordinary immuno...
主要な著者: | , , , |
---|---|
フォーマット: | Online 論文 テキスト |
言語: | English |
出版事項: |
MDPI
2021
|
主題: | |
オンライン・アクセス: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959120/ https://www.ncbi.nlm.nih.gov/pubmed/33802281 http://dx.doi.org/10.3390/ijms22052517 |
要約: | Many immuno-therapeutic strategies are currently being developed to fight cancer. In this scenario, oncolytic adenoviruses (Onc.Ads) have an interesting role for their peculiar tumor selectivity, safety, and transgene-delivery capability. The major strength of the Onc.Ads is the extraordinary immunogenicity that leads to a strong T-cell response, which, together with the possibility of the delivery of a therapeutic transgene, could be more effective than current strategies. In this review, we travel in the adenovirus (Ads) and Onc.Ads world, focusing on a variety of strategies that can enhance Onc.Ads antitumoral efficacy, passing through tumor microenvironment modulation. Onc.Ads-based therapeutic strategies constitute additional weapons in the fight against cancer and appear to potentiate conventional and immune checkpoint inhibitors (ICIs)-based therapies leading to a promising scenario. |
---|